ORAL L-CARNITINE SUPPLEMENTATION IN CARDIORENAL HEART FAILURE PATIENTS

Registry ID

REDA-16078

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

LONDON HEALTH SCIENCES CENTRE

Start date

2026-01-21

Last update

2025-10-28

Conditions

• HEART FAILURE

Related clinical trials

• EFFICACY AND SAFETY OF NNC0487-0111 COMPARED TO PLACEBO ON MORBIDITY AND MORTALITY IN PEOPLE WITH HEART FAILURE WITH PRESERVED OR MILDLY REDUCED EJECTION FRACTION AND OBESITY (HF-POLARIS)
• A MULTI-CENTER, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR- BLINDED, PLACEBO-CONTROLLED CROSSOVER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF HJB647 IN PARTICIPANTS WITH CHRONIC STABLE HEART FAILURE WITH REDUCED OR MILDLY REDUCED EJECTION FRACTION (HFREF/HFMREF)
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND PK/ PD OF FINERENONE, IN ADDITION TO STANDARD-OF-CARE, IN PEDIATRIC PATIENTS, 6 MONTHS TO < 18 YEARS OF AGE WITH HEART FAILURE (HF) AND LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)
• A PHASE 3, SINGLE-ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF FINERENONE IN ADDITION TO STANDARD OF CARE, IN PEDIATRIC HEART FAILURE PATIENTS, FROM BIRTH TO 18 YEARS OF AGE, WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)
• A PHASE 2, MULTICENTER, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE EFFECTS OF SOTATERCEPT FOR THE TREATMENT OF COMBINED POSTCAPILLARY AND PRECAPILLARY PULMONARY HYPERTENSION (CPC-PH) DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)
• A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO ASSESS EFFICACY AND SAFETY OF OMECAMTIV MECARBIL IN PATIENTS WITH SYMPTOMATIC HEART FAILURE WITH SEVERELY REDUCED EJECTION FRACTION

View on source registry